Roth M
Internist und Kardiologe, Oberarzt an der Stiftsklinik Augustinum, München.
MMW Fortschr Med. 1999 Jul 22;141(28-29):30-4.
Therapeutic options in acute coronary syndrome (unstable angina pectoris/non-Q-wave myocardial infarction), as also in acute Q-wave infarction, include conservative medical and mechanical-interventional measures. Early hospitalization for surveillance and induction of treatment is always necessary. Administration of oxygen, analgesia, sedation and treatment with nitrates, beta blockers or calcium antagonists, acetylsalicylic acid (ASA) and heparin are the basic measures. As alternatives to ASA, the new ADP antagonists, ticlopidine, clopidogrel, and as an alternative to heparin, hirudin or low-molecular-weight heparins can be used. If this does not result in rapid clinical stabilisation (here, transient ST-T changes in the ECG and the detection of troponine I or T represent major risk indicators) the new glycoprotein-IIb/IIIa receptor antagonists may be employed as highly potent platelet aggregation inhibitors. In addition, the patients should then undergo coronary angiography prior to interventional treatment of the underlying coronary stenosis.
急性冠状动脉综合征(不稳定型心绞痛/非Q波心肌梗死)以及急性Q波梗死的治疗选择,包括保守的药物治疗和机械介入措施。早期住院进行监测和诱导治疗总是必要的。给予氧气、镇痛、镇静以及使用硝酸盐、β受体阻滞剂或钙拮抗剂、乙酰水杨酸(ASA)和肝素是基本措施。作为ASA的替代药物,可使用新型ADP拮抗剂噻氯匹定、氯吡格雷;作为肝素的替代药物,可使用水蛭素或低分子量肝素。如果这不能导致临床快速稳定(在此,心电图上短暂的ST-T改变以及肌钙蛋白I或T的检测是主要风险指标),则可使用新型糖蛋白IIb/IIIa受体拮抗剂作为高效的血小板聚集抑制剂。此外,患者随后应在对潜在冠状动脉狭窄进行介入治疗之前接受冠状动脉造影。